We found KRAS mutation in colorectal cancer drove immune evasion by sensitizing cytotoxic T‐cells to activation‐induced cell death via lactic acid‐mediated NF‐κB inactivation, and impaired the efficacy of anti‐PD‐1 and adoptive T‐cell therapy. Here, NFKB1 is linked to colorectal cancer.